晨光生物科技集团股份有限公司（以下简称"公司"）监事会于2023年10 月24日以专人送达、电话方式向全体监事发出第五届监事会第五次会议通知，会 议于2023年10月31日在公司会议室以现场表决方式召开。本次会议由监事会主席 翟艳忠先生主持，应出席会议监事三人，实际出席会议监事三人。本次会议召开 符合《公司法》《公司章程》等有关规定。经与会监事研究、讨论，审议通过以 下议案： 一、审议通过了《关于回购公司股份方案的议案》 经审核，监事会认为：公司回购股份符合《公司法》《证券法》《深圳证券交 易所创业板股票上市规则》《上市公司股份回购规则》《深圳证券交易所上市公司 自律监管指引第 9 号——回购股份》等相关规定。董事会会议的召集、出席人数、 表决程序符合有关法律法规和《公司章程》的有关规定。结合公司实际经营及未 来发展，回购股份不会对公司的经营、财务及未来发展产生重大影响。回购后不 会导致公司控制权发生变化，不会改变公司的上市公司地位，股权分布情况仍符 合上市的条件。公司回购股份有利于维护全体股东利益，维护公司市场形象，增 强投资者信心。 证券代码：300138 证券简称：晨光生物 公告编号：2023—150 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—151 晨光生物科技集团股份有限公司 关于回购公司股份方案的公告 2、截至本公告披露日，公司未收到董事、监事、高级管理人员、持股 5%以 上股东或其一致行动人在回购期间的增减持股份计划，若未来前述主体提出增减 持计划，公司将按照相关规定及时履行信息披露义务。 3、相关风险提示 本次回购事项存在回购期间内因股票价格持续超出回购价格上限而导致本 次回购方案无法顺利实施或者部分实施等不确定风险；存在因对公司股票交易价 格产生重大影响的重大事项发生或公司股东大会决定终止本次回购方案等而无 法实施的风险；存在公司股东大会未审议通过回购股份议案的风险；公司无法满 足债权人要求清偿债务或提供相应的担保，进而导致回购方案无法实施的风险。 基于对公司未来发展前景的信心和对公司价值的高度认可，综合考虑公司近 期股票二级市场表现，为维护投资者利益，增强投资者信心，根据《公司法》《证 券法》《深圳证券交易所创业板股票上市规则》《上市公司股份回购规则》《深 圳证券交易所上市公司自律监管指引第 9 号——回购股份》等法律、法规及规范 性文件的有关规定，公司计划以自有资金进行 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—153 晨光生物科技集团股份有限公司 关于召开 2023 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次股东大会召开的基本情况 4、本次股东大会召开的日期、时间 现场会议召开时间：2023 年 11 月 17 日下午 14:50。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2023 年 11 月 17 日上午 9:15—9:25，9:30—11:30，下午 13:00—15:00；通过深圳证 券交易所互联网投票系统投票的时间为：2023 年 11 月 17 日上午 9:15 至下午 15:00 期间的任意时间。 5、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 股东只能选择现场投票、网络投票中的一种方式，如果同一表决权出现重复 投票表决的，以第一次投票表决结果为准。 1、股东大会届次：2023 年第三次临时股东大会 2、会议召集人：公司董事会，本次股东大会的召开已经公司第五届董事会 第五次会议审议通过。 3、会议召开的合法 ...

独立董事：戴小枫、厉梁秋、牛翃 1、公司本次回购股份符合《公司法》《证券法》《深圳证券交易所创业板 股票上市规则》《上市公司股份回购规则》《深圳证券交易所上市公司自律监管 指引第9号——回购股份》等法律、法规及规范性文件的有关规定，董事会表决 程序符合法律法规和规章制度的相关规定。 2、基于对公司未来发展前景的信心和对公司价值的高度认可，综合考虑公 司股票二级市场表现、经营情况及业务未来发展前景等情况，公司决定回购股份 予以依法注销减少注册资本。本计划的实施，有利于增强广大投资者的信心，有 利于维护公司全体股东的利益。 3、本次使用自有资金总额不低于人民币0.5亿元（含）且不超过人民币1亿 元（含）。根据公司目前经营情况、财务状况及未来发展规划，本次回购不会对 公司的经营、财务和未来发展产生重大影响，不会影响公司的上市地位。 综上，我们认为公司本次回购公司股份方案及决策程序合法、合规，不存在 损害公司及全体股东权益的情形，本次回购方案具有可行性。同意将本次回购股 份事项提交公司股东大会审议。 晨光生物科技集团股份有限公司独立董事 关于公司第五届董事会第五次会议相关事项的独立意见 根据《公司法》《证券法》《上市 ...

晨光生物科技集团股份有限公司 章 程 | | | | 第一章 | 总 | 则 1 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 2 | | 第三章 | 股 | 份 3 | | 第四章 | | 股东和股东大会 6 | | 第五章 | | 董事会 22 | | 第六章 | | 高级管理人员 33 | | 第七章 | | 监事会 35 | | 第八章 | | 财务会计制度、利润分配和审计 37 | | 第九章 | | 通知与公告 42 | | 第十章 | | 合并、分立、增资、减资、解散和清算 43 | | 第十一章 | | 修改章程 45 | | 第十二章 | | 附 则 46 | 晨光生物科技集团股份有限公司 章 程 第一章 总 则 第一条 为维护晨光生物科技集团股份有限公司（以下简称"公司"或"本 公司"）、股东和债权人的合法权益，规范公司的组织和行为，根据《中华人民 共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下 简称"《证券法》")、《上市公司章程指引》（2022 年修订）、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—149 晨光生物科技集团股份有限公司 第五届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）董事会于2023年10 月24日以专人送达、邮件方式向全体董事发出第五届董事会第五次会议通知，会 议于2023年10月31日在公司会议室以现场与通讯相结合的方式召开。本次会议由 董事长卢庆国先生主持，应出席会议董事六人，实际出席会议董事六人（独立董 事戴小枫、厉梁秋、牛翃以通讯表决方式出席），公司监事列席了本次会议。本 次会议召开符合《公司法》《公司章程》等有关规定。经与会董事研究、讨论， 审议通过以下议案： 一、审议通过了《关于回购公司股份方案的议案》 1、回购股份的目的及用途 本次回购股份的价格为不超过人民币 16.5 元/股（含）。该回购股份的价格 上限不高于董事会通过回购决议前三十个交易日公司股票交易均价的 150%，实 际回购股份价格由股东大会授权公司董事会在回购启动后视公司股票具体情况 确定。如公司在回购股份的期限内实施了 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—147 晨光生物科技集团股份有限公司 关于为子公司银行借款提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 晨光生物科技集团股份有限公司（简称"公司"）第四届董事会第四十八次 会议、2022 年年度股东大会审议通过了《关于向融资机构申请办理各类融资业 务的议案》，同意公司及合并报表范围内各级子公司在 2022 年年度股东大会审 议通过之日起至 2023 年年度股东大会召开日，向融资机构申请办理各类融资业 务余额不超过 55 亿元。 融资担保方式涉及公司合并报表范围内各主体之间担保：公司向合并报表范 围内各级子公司或各级子公司之间融资担保余额不超过 31 亿元，其中：向子公 司新疆晨光生物科技股份有限公司（简称"新疆晨光"）及其合并报表范围内子 公司提供担保的余额不超过 24.5 亿元，向其他子公司提供担保或其他子公司之 间互相担保的余额不超过 6.5 亿元。股东大会授权管理层在融资担保余额不超过 31 亿元的前提下，结合合并报表范围内各子公司资产负债率、融资授信 ...

Group 1: Financial Performance - In the first three quarters of 2023, the company achieved operating revenue of 5.169 billion yuan, a year-on-year increase of 7.78% [1] - In Q3 2023, the operating revenue was 1.501 billion yuan, a decrease of approximately 4.36% year-on-year [1] - Net profit attributable to shareholders for the first three quarters was 398 million yuan, a year-on-year increase of 18.29% [2] - Q3 net profit attributable to shareholders was 99.97 million yuan, a year-on-year increase of 3.46% [2] Group 2: Business Segment Performance - Revenue from plant extraction business in Q3 was 646 million yuan, a year-on-year increase of approximately 2% [1] - Revenue from cottonseed business in Q3 was 789 million yuan, a year-on-year decrease of approximately 11% [1] - Sales volume of chili red pigment increased by 15% year-on-year, while chili extract sales volume grew by 18% [2] - Sales volume of feed-grade lutein decreased by approximately 60% year-on-year, while food-grade lutein sales volume increased by approximately 70% [2] Group 3: Market and Product Development - The company is actively developing differentiated and customized products to enhance customer problem-solving capabilities and increase product added value [2] - The health food business achieved sales exceeding 100 million yuan, a year-on-year increase of over 70% [2] - The company is expanding its raw material base, with significant growth in planting areas for marigold in India and Zambia [3] Group 4: Seasonal Trends and Future Outlook - Cottonseed business typically sees concentrated procurement of raw materials in Q4 and Q1 of the following year [4] - The company plans to launch new projects in the cottonseed business in Q4, with production gradually ramping up to design capacity [3] - The health food business is expected to maintain an upward trend in profit margins due to improved customer structure and scale effects [5]

证券代码：300138 证券简称：晨光生物 公告编号：2023—145 晨光生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 近期，公司使用部分暂时闲置募集资金进行了现金管理，具体情况如下： 一、本次购买理财产品情况 1、发行人名称：中山证券有限责任公司 2、产品名称：中山证券尊享 75 号固定收益凭证 3、产品类型：本金保障型固定收益凭证 4、产品起息日：2023 年 10 月 24 日 5、产品到期日：2024 年 07 月 24 日 6、预期年化收益率：3.30% 7、认购金额：5,000 万元 8、资金来源：闲置募集资金 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）于 2023 年 9 月 21 日召开的第五届董事会第三次会议、第五届监事会第三次会议审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》。同意公司在不影响募集资金投资 项目建设的前提下，使用不超过 2 亿元暂时闲置募集资金进行现金管理，用于购 买安全性高、流动性好的理财产品/结构性存款产品等，期限为自董事会审 ...

Financial Performance - The company's revenue for Q3 2023 was ¥1,500,747,199.05, a decrease of 4.36% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥99,701,156.24, an increase of 3.46% year-on-year[4]. - The net profit excluding non-recurring gains and losses was ¥90,103,951.26, up by 1.99% compared to the previous year[4]. - The basic earnings per share for Q3 2023 was ¥0.19, representing a 5.56% increase year-on-year[4]. - Total operating revenue for Q3 2023 reached ¥5,169,444,187.28, an increase of 7.8% compared to ¥4,796,296,740.75 in Q3 2022[35]. - Net profit for Q3 2023 was ¥416,111,137.75, representing a 22.9% increase from ¥338,498,870.32 in Q3 2022[36]. - The company reported a comprehensive income total of ¥429,534,028.97 for Q3 2023, compared to ¥368,498,963.22 in Q3 2022, an increase of 16.5%[36]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥7,429,668,380.17, reflecting a growth of 7.31% from the end of the previous year[5]. - The company's total assets increased to ¥7,429,668,380.17 in Q3 2023, compared to ¥6,923,739,569.28 in Q3 2022, marking a growth of 7.3%[34]. - The company's total liabilities amounted to ¥3,873,496,476.58 in Q3 2023, compared to ¥3,709,657,856.10 in Q3 2022, reflecting a rise of 4.4%[34]. - Non-current assets totaled ¥2,137,135,551.84 in Q3 2023, up from ¥1,996,966,856.54 in Q3 2022, indicating an increase of 7.0%[34]. Cash Flow - The company's cash flow from operating activities showed a significant decline of 41.33%, totaling ¥995,638,605.50 year-to-date[4]. - Net cash flow from operating activities decreased by 41.33% year-on-year, primarily due to changes in various cash flow components from operating activities[14]. - Cash inflow from operating activities totaled ¥5,222,452,862.69, a decrease of 3.9% compared to ¥5,434,526,944.86 in Q3 2022[37]. - Net cash flow from operating activities was ¥995,638,605.50, down 41.4% from ¥1,697,041,867.19 in the previous year[37]. - Cash inflow from investment activities was ¥1,030,026,484.00, an increase of 21.8% compared to ¥845,698,510.93 in Q3 2022[38]. - Net cash flow from investment activities was -¥18,319,902.96, improving from -¥583,565,873.57 in the same period last year[38]. - Cash inflow from financing activities was ¥2,786,703,439.90, down 9.7% from ¥3,086,033,012.12 in Q3 2022[38]. - Net cash flow from financing activities was ¥289,159,193.02, compared to a negative cash flow of -¥121,883,835.12 in the previous year[38]. - The ending balance of cash and cash equivalents was ¥2,092,404,812.87, an increase from ¥1,754,948,773.44 at the end of Q3 2022[38]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,142[18]. - The largest shareholder, Lu Qingguo, holds 18.43% of shares, totaling 98,196,051 shares, with 73,647,038 shares pledged[18]. - The number of ordinary shareholders increased from 12,031 at the end of July 2023 to 12,657 at the end of August 2023[19]. Research and Development - Research and development expenses decreased by 37.75% compared to the same period last year, indicating a reduction in project investment[12]. - Research and development expenses for Q3 2023 were ¥61,110,369.60, down from ¥98,167,189.31 in Q3 2022, showing a decrease of 37.7%[36]. - The company is focusing on technology research and development, with ongoing projects aimed at improving production processes and product quality[28]. - The company is actively developing new products, including customized and specialized products to enhance customer solutions[24]. - The company has completed the development of new extraction processes for ginger and pepper, enhancing product competitiveness and profit margins[29]. - The company has launched several new products, including microencapsulated products and specialized application products, aimed at expanding its product range and market presence[29]. - The company has successfully registered new health food products, including fish oil soft capsules and coenzyme Q10 soft capsules, to enhance its market competitiveness[30]. - The company has made progress in the comprehensive utilization of chili, completing feasibility studies for new resource applications in food products[30]. - The company has developed a new extraction process for sophora japonica, improving the yield of rutin and addressing environmental concerns associated with traditional methods[30]. - The company has completed the production transformation of compound Danshen tablets and motherwort granules, expanding its traditional Chinese medicine product offerings[29]. - The company is actively conducting market research and product development to identify new profit growth points and enhance overall market competitiveness[29]. Inventory and Current Assets - The company optimized its inventory management, with inventory decreasing from CNY 2,033,380,620.48 to CNY 1,350,895,378.40, reflecting a reduction of approximately 33.7%[32]. - The total current assets reached CNY 5,292,532,828.33, up from CNY 4,926,772,712.74, indicating an increase of about 7.4%[32]. - As of September 30, 2023, the company's cash and cash equivalents increased to CNY 2,294,254,913.51 from CNY 1,146,656,571.64 at the beginning of the year, representing a growth of approximately 100%[32]. Other Income and Expenses - Other income increased by 113.41% year-on-year, driven by government grants and subsidies received during the reporting period[12]. - Other comprehensive income decreased by 55.26% compared to the same period last year, mainly due to reduced foreign currency translation differences from exchange rate fluctuations[14]. - Cash received from investment income increased by 313.87% year-on-year, attributed to dividends from associates and cash flow from short-term financial management[14]. - Net cash flow from investment activities increased by 96.86% year-on-year, driven by the recovery of financial management funds and returns exceeding the previous year[14]. - The cash received from other financing activities increased by 100% year-on-year, mainly due to increased cash inflow from pledged deposits[16]. - The impact of exchange rate fluctuations on cash decreased by 214.62% year-on-year, reflecting changes in foreign currency settlements in import and export businesses[16]. Company Overview - The company achieved a revenue of 5.169 billion yuan in the first three quarters of 2023, representing a year-on-year growth of 7.78%[23]. - The net profit attributable to shareholders reached 398 million yuan, an increase of 18.29% year-on-year[23]. - Sales from the chili red pigment segment grew by 15% year-on-year, while chili extract sales increased by 18%[23]. - The health food business generated over 100 million yuan in sales, marking a growth of over 70%[25]. - The company is expanding its raw material bases, with significant growth in planting areas in India and Zambia[26]. - The cottonseed business maintained steady operations, effectively managing raw material procurement and product sales[27]. - The company is promoting differentiated products and enhancing production efficiency in the stevia sugar segment[23]. Reporting and Audit - The company did not undergo an audit for the Q3 report[39]. - The report was released by the board of directors on October 23, 2023[40].